Lixisenatid - ein neuer GLP-1-Agonist

ISSN： 2195-2175

Source： PHARMAKON, Vol.1, Iss.3, 2013-05, pp. : 198-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Wieder einmal ein neuer Ansatz gegen HIV-1

PHARMAKON, Vol. 3, Iss. 4, 2015-07 ,pp. : 252-254

Govi-Verlag

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele Bajaj Mandeep

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice

Canadian Journal of Physiology and Pharmacology, Vol. 92, Iss. 12, 2014-01 ,pp. : 975-983

NRC Research Press

Access to resources Recommend Favorite

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice

By Joharapurkar Amit Dhanesha Nirav Kshirsagar Samadhan Patel Kartik Bahekar Rajesh Shah Gaurang Jain Mukul

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 12, 2013-01 ,pp. : 1009-1015

NRC Research Press

Access to resources Recommend Favorite

Delamanid: Ein neuer Wirkstoff gegen Tuberkulose

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 376-377

Govi-Verlag

Access to resources Recommend Favorite